Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; Findings and implications for other countries

International Journal of Clinical Practice

Volumn 67, Issue 9, 2013, Pages 853-862

  Godman, B ^a,b,c   Wettermark, B ^a,d   Miranda, J ^e   Bennie, M ^c,f   Martin, A ^g   Malmstrom R E ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

^f INFORMATION SERVICES DIVISION   (United Kingdom)

^g NHS Bury   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG USE; HEALTH CARE AVAILABILITY; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MONOTHERAPY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SWEDEN; TIME SERIES ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; COST SAVINGS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; HEALTH EXPENDITURES; HUMANS; HYPERTENSION; LOSARTAN; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84882452324     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12130     Document Type: Article

References (54)

1. Godman B, Buscics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P,. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 199-207.
2. Vončina L, Strizrep T, Godman B, et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 469-79.
3. Office of Fair Trading. Current price inefficiencies and potential benefits of value-based pricing. February 2007. http://www.oft.gov.uk/shared- oft/reports/comp-policy/oft885 m.pdf (accessed October 2012).
4. NHS Better Care Better Value Indicators: http://www.productivity.nhs.uk/ Indicator/625/For/National/And/25th/Percentile (accessed October 2012).
5. Godman B, Malmstrom RE, Bennie M, Sakshaug S, et al. Prescribing restrictions-a necessary strategy among some European countries to enhance future prescribing efficiency?. Reviews in Health Care 2012; 3: 5-16.
6. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 1. 2008; 148: 16-29.
7. Frisk P, Mellgren T-O, Hedberg N, et al. Utilisation of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur Jn Clin Pharmacol 2008; 64: 1223-9.
8. Fletcher A, Palmer A, Bulpitt C,. Coughing with angiotensin converting enzyme inhibitors; how much of a problem?. J Hypertens 1994; 12: S43-7.
9. Elliot H,. Focus on the ONTARGET results. J Hypertens 2009; 27: S8-10.
10. Norman C, Zarrinkoub R, Hasselström J, Godman B, et al. Potential savings without compromising the quality of care. Int J Clin Pract 2009; 63: 1320-6.
11. Cramer JA, Benedict A, Muszabek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008; 62: 76-87.
12. Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL,. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 65-83.
13. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, et al. The "Wise List"-a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011; 108: 224-33.
14. Wettermark B, Godman B, Neovius M, Hedberg N, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010; 94: 221-9.
15. Godman B, Paterson K, Malmstrom R, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 439-41.
16. Markovic-Pekovic V, Ranko Škrbic̈ R, Godman B, Gustafsson LL,. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcome Res 2012; 5: 661-71.
17. Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns-a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009; 17: 179-89.
18. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M,. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008; 62, 480-4.
19. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A,. Getting better value from the NHS drug budget. BMJ 2011; 342: 30-2.
20. Godman B, Bennie M, Baumgärtel C, Sovic̈ Brkičic̈ L, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia. Health economics and therapeutic pathways 2012; 13 (Suppl. 3): 5-20.
21. Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 475-84.
22. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A,. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 121-9.
23. Regional Drugs and Therapeutic Centre (NHS). Fixed-dose combinations (Part 2)-Use in specific medical conditions. October 2008. http://www.nyrdtc. nhs.uk/docs/dud/DU-62-Fixed-Dose-Combinations-(2).pdf (accessed October 2012).
24. Heran BS, Wong MM, Heran IK, Wright JM,. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008; Issue 4: CD003823.
25. NICE updates its guidance on the management of hypertension. MeReC 10 October 2011. http://www.npc.nhs.uk/rapidreview/?p = 4470 (accessed September 2012).
26. MeReC. Key Therapeutic Targets; Medicines Management Options for Local Implementation. July 2011. http://www.npc.nhs.uk/qipp/resources/qipp-key- therapeutic-topics-july11-version3.1.v2.pdf (accessed October 2012).
27. Svanstrom H, Pasternak B, Hviid A,. Association of treatment with losartan vs candesartan and mortality among Patients with heart failure. JAMA 2012; 307: 1506-12.
28. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2099; 374: 1840-8.
29. MeReC. February 2012. Key Therapeutic Targets; Medicines Management Options for Local Implementation. http://www.npc.nhs.uk/qipp/resources/Key- therapeutic-topics-Medicines-Management-for-local%20implementation-feb%202012- final.pdf (accessed March 2012).
30. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005; 14: 341-8.
31. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele' V,. Recent national and regional drug reforms in Sweden-implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26: 537-50.
32. Godman B, Abuelkhair M, Vitry A, Abdu S, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 2012; 1 (): 69-83.
33. World Health Organisation (WHO) Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2009. www.whocc.no (accessed August 2012).
34. World Health Organization (WHO). Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). http://www.who.int/medicines/areas/ quality-safety/safety-efficacy/Drug%20utilization%20research.pdf (accessed August 2012).
35. Rønning M, Blix HS, Harbø BT, Strøm H,. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose-are drug utilisation data comparable? Eur J Clin Pharmacol 2000; 56: 723-7.
36. Vlahovic-Palcevski V, Gantumur M, Radosevic N, et al. Coping with changes in Defined Daily Dose in longitudinal drug consumption databases. Pharm World Sci 2010; 32: 125-9.
37. McDowall D, et al. Interrupted Time Series Analysis. In: Sage University Papers Series on Quantitative Applications in the Social Sciences. Thousand Oaks, CA: Sage Publications Inc, 1980: 7021 pp.
38. Ross-Degnan D, et al. Examining product risk in context. Market withdrawal of zomepirac as a case study. JAMA 1993; 270: 1937-42.
39. Durbin J, Watson GS,. Testing for serial correlation in least square regression. Biometrika 1951; 37: 409-28.
40. Brennan P, Croft P,. Interpreting the results of observational research: chance is not such a fine thing. BMJ 1994; 309: 727-30.
41. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F,. Soft regulations in pharmaceutical policymaking-an overview of current approaches and their consequences. Appl Health Econ Health Policy 2009; 7: 137-47.
42. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1988; 317: 465-8.
43. Barton S,. Using clinical evidence. BMJ 2001; 322: 503-4.
44. Godman B, Bennett K, Bennie M, Burkhardt, et al. Variable approaches to enhancing the prescribing of losartan once generics available; influence and future direction. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl. 3): 295.
45. Bennie M, Godman B, Bishop I, Campbell S,. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 125-30.
46. Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 569-81.
47. Holden J,. Hawthorne effects and research into clinical practice. J Eval Clin Pract 2001; 7: 65-70.
48. Konstantinou G,. Pragmatic trials: how to adjust for the 'Hawthorne effect'? Thorax 2012; 67: 562.
49. Trietsch J, van der Weijden T, Verstappen W, et al. A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol. Implement Sci 2009; 4: 6. doi: 10.1186/1748-5908-4-6.
50. Verstappen WHJM, Weijden T, van der ter Riet G, Grimshaw J, Winkens R, Grol R,. Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering. J Clin Epidemiol 2004; 57: 1119-23.
51. Parsons, H. M,. " What happened at Hawthorne? New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies ". Science 1974; 183 (): 922-32.
52. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
53. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2004; 27: S65-7.
54. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.